Aeterna Zentaris


About: AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna's lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $65.2K [Q4 2023] → $106K (+$40.4K) [Q1 2024]

0.28% more ownership

Funds ownership: 0.73% [Q4 2023] → 1.0% (+0.28%) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

15% less funds holding

Funds holding: 13 [Q4 2023] → 11 (-2) [Q1 2024]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Research analyst outlook

We haven’t received any recent analyst ratings for AEZS.

Financial journalist opinion